New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
07:23 EDTSRPTSarepta upgraded to Buy from Hold at Needham
Needham upgraded Sarepta due to valuation and continued positive data from the eteplirsen Phase IIb trial. Price target is $36.
News For SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2015
10:38 EDTSRPTOptions with increasing implied volatility
Subscribe for More Information
July 27, 2015
10:40 EDTSRPTIsis 'most obvious' Biogen takeover target, TheStreet's Feuerstein says
Subscribe for More Information
July 22, 2015
17:06 EDTSRPTSarepta announce publication of Phase I clinical data of AVI-7288
Subscribe for More Information
July 20, 2015
14:32 EDTSRPTFDA panel likely to review Sarepta, BioMarin drugs in November, TheStreet says
Subscribe for More Information
11:03 EDTSRPTSarepta rises after Roth says added data can keep it ahead of BioMarin
Subscribe for More Information
10:13 EDTSRPTOptions with decreasing implied volatility
Subscribe for More Information
July 16, 2015
10:18 EDTSRPTOptions with increasing implied volatility
Options with increasing implied volatility: SRPT ENR FOSL KING

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use